CNBX on OTC
CNBX Pharmaceuticals Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Serina Therapeutics, Inc., SOLIGENIX, INC. or BullFrog AI Holdings, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-100.0%Revenue growth, 20252
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-08-31 | 2024-08-31 |
|---|---|---|
| Revenues | $0 | $130.1K |
| Research and development expense | $0 | $194.8K |
| General and administrative expenses | $271.7K | $518.4K |
| Total operating expenses | $271.7K | $713.2K |
| Loss from operations | -$271.7K | -$583.1K |
| Capital loss | $0 | $88.9K |
| Financial loss, net | $42.3K | $23.1K |
| Net (loss) income | -$314.0K | -$695.2K |
| Total comprehensive (loss) income | -$314.0K | -$695.2K |
| Net (loss) per share - basic | $0.00 | -$0.02 |
| Net (loss) per share - diluted | $0.00 | -$0.02 |
| Weighted average number of shares outstanding - Basic | 90.6M shares | 30.2M shares |
| Weighted average number of shares outstanding - Diluted | 90.6M shares | 30.2M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-08-31 | 2024-08-31 | 2023-08-31 |
|---|---|---|---|
| Cash and cash equivalents | $15.1K | $26.4K | |
| Prepaid expenses and other receivables | $3.3K | $5.0K | |
| Total current assets | $18.4K | $31.4K | |
| Equipment, net | $0 | $0 | |
| Total assets | $18.4K | $31.4K | |
| Accounts payable and accrued liabilities | $49.3K | $40.8K | |
| Convertible loan | $1.2M | $1.3M | |
| Due to a related party | $1.3M | $1.2M | |
| Total current liabilities | $2.5M | $2.5M | |
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.0001 par value, 1,800,000,000 and 900,000,000 shares authorized on August 31, 2025 and August 31, 2024 respectively. 553,962,206 and 31,111,352 shares issued and outstanding on August 31, 2025 and August 31, 2024 respectively | $55.4K | $3.1K | |
| Additional paid-in capital | $22.7M | $22.5M | |
| Accumulated deficit | -$25.3M | -$25.0M | |
| Total stockholders' equity (deficit) | -$2.5M | -$2.5M | -$2.0M |
| Total liabilities and stockholders' equity | $18.4K | $31.4K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.8B shares | 900.0M shares | |
| Common stock, shares issued | 554.0M shares | 31.1M shares | |
| Common stock, shares outstanding | 554.0M shares | 31.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-08-31 | 2024-08-31 |
|---|---|---|
| Net (Loss) | -$314.0K | -$695.2K |
| Depreciation | $0 | $72.3K |
| Share based payment | $0 | $139.7K |
| Interest on Convertible loan | $39.8K | $16.8K |
| Capital loss (Gain) | $0 | $88.9K |
| Accounts Receivable and prepaid expenses | $1.6K | $89.6K |
| Accounts payable and accrued liabilities | $101.2K | $43.5K |
| Net cash used in operating activities | -$171.3K | -$244.3K |
| Sale of equipment | $0 | $114.7K |
| Acquisition of equipment | $0 | -$1.2K |
| Net cash used in investing activities | $0 | $113.5K |
| Proceeds from issuance of a Convertible loan | $160.0K | $27.5K |
| Net cash provided by financing activities | $160.0K | $27.5K |
| Net increase (decrease) in cash | -$11.3K | -$103.3K |
| Exercise of a Convertible loan to shares of common stock. | $297.7K | $92.8K |
Former names
Recent filings
- Oct 1, 20268-K CURRENT REPORT
- Aug 14, 2026SCHEDULE 13G/A
- Jun 24, 202610-Q FORM 10-Q FOR MAY 2026
- May 8, 2026SCHEDULE 13G/A
- Apr 14, 202610-Q
- Mar 17, 20268-K
- Feb 5, 2026SCHEDULE 13G/A
- Jan 14, 202610-Q QUARTERLY REPORT
- Dec 1, 202510-K FORM 10-K FOR AUG 2025
- Nov 10, 2025SCHEDULE 13G/A
- Aug 13, 2025SCHEDULE 13G/A
- Jul 14, 202510-Q
- May 13, 2025SCHEDULE 13G/A
- Apr 14, 202510-Q
- Feb 13, 2025SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12